An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
First ECHO Pitch 2019 competition a huge success, unanimous winner takes $250,000 in startup funding
At ECHO PITCH 2019, one startup earned $250K in funding
Ted Rogers Centre investigator’s medical implant technology set to go global
Paul Santerre’s latest commercialization success
Why we must screen early in life for hypertrophic cardiomyopathy
New study aims to change screening guidelines
ECHO program supports efforts to prevent ischemia-reperfusion injury in the heart
A novel peptide may solve this phenomenon
Our 2019 Innovation Fund awards: 3D models of heart failure… stiffened hearts in diabetes…. saving infant lives
Three bold projects target special challenges in HF
Study uncovers key differences in the journey of heart patients in northern and southern Ontario
Less access to specialists may increase readmission risk
World-first technology to clear the heart of dangerous protein deposits
‘Desperate need for therapies for AL amyloid cardiomyopathy’
Ted Rogers Centre director leads new landmark diabetes paper
PIONEER 6 finds novel GLP-1 RA is safe for the heart
B-cell deficiency found to lower blood pressure
B-cell deficiency found to lower blood pressure
2019 Heart Failure Symposium attracts 380 attendees
Included first-ever special event for family doctors